Sevelda P, Barrada M, Vavra N, Denison U, Schmidl S, Genger H, Salzer H
Gynäkologisch-onkologische Arbeitsgruppe der I. Universitäts-Frauenklinik, Wien.
Wien Klin Wochenschr. 1990 Aug 3;102(15):441-3.
40 patients with advanced epithelial ovarian carcinoma were investigated to evaluate the influence of further cytoreduction during second-look surgery on survival after termination of first-line polychemotherapy containing cisplatinum. Radical tumorectomy with no macroscopic residual tumor mass was achieved in 27.5% of cases; in 52.5% the residual tumour mass was less than 2 cm and in 20% it was more than 2 cm in diameter after cytoreductive second-look surgery. Median survival time after second-look within these three groups of patients was 15.2 months, 16.9 months and 15.3 months, respectively (Mantel test, p = 0.74). In contrast to the situation at the diagnostic operation, further cytoreduction during second-look surgery has no positive influence on survival. We therefore abandoned this operation in clinically tumour-positive patients.
对40例晚期上皮性卵巢癌患者进行了研究，以评估二次探查手术时进一步减瘤对含顺铂一线多药化疗结束后生存率的影响。27.5%的病例实现了根治性肿瘤切除术，无肉眼可见的残留肿瘤；二次探查减瘤手术后，52.5%的患者残留肿瘤小于2cm，20%的患者残留肿瘤直径大于2cm。这三组患者二次探查后的中位生存时间分别为15.2个月、16.9个月和15.3个月（Mantel检验，p = 0.74）。与诊断性手术时的情况不同，二次探查手术时进一步减瘤对生存率没有积极影响。因此，我们在临床肿瘤阳性患者中放弃了这种手术。
